Article Archived Jun 19, 2020
Backed by a new leadership team, ASX-listed biotech junior, eSense-Lab (ASX:ESE) is implementing a new business model that sees it enter joint venture (JV) agreements to quickly reach multiple revenue-generating markets.
Article Archived May 05, 2020
OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.
Article Archived Mar 24, 2020
Creso Pharma Limited (ASX: CPH) is expanding its available product line with the release of a hemp tea in Q3 2020.
Article Archived Jan 30, 2020
OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.
Article Archived Jan 28, 2020
Creso Pharma (ASX:CPH, FRA:1X8) has announced its second major milestone for the year. Today is has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The 100,000 pack milestone corresponds to over 2.5 million cannaQIX® lozenges sold since the product’s launch in April 2018.
Article Archived Dec 19, 2019
One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).
Article Archived Nov 07, 2019
One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.
Article Archived Jul 02, 2019
Who is the ASX company with transforming qualities that could completely disrupt the cannabis and CBD markets?
Thanks for subscribing!